Position statement on the use of biosimilars in inflammatory bowel disease

A biosimilar is a biological medicine highly similar to another, already approved medicine. Physicians should be aware of definition, approval process, and biochemical and clinical features that distinguish biosimilars from the reference product.

Immunosuppressant therapeutic drug monitoring and trough level stabilisation after paediatric liver or kidney transplantation

Immunosuppressive therapy must be guided by therapeutic drug monitoring (TDM) in paediatric liver (LT) and kidney transplantation (KT) patients to prevent under- and overdosing, which have clinical consequences.

Incidental findings during computed tomographic angiography diagnostic work-up in patients with arteriogenic erectile dysfunction

Erectile dysfunction (ED) has recently been identified as a predictor of generalised vascular disease and, besides the functional sexual impairment, symptoms of ED may be indicative of underlying risk factors or cardiovascular comorbidities.

Secondary hyperparathyroidism: recurrence after total parathyroidectomy with autotransplantation

If drug therapy for secondary hyperparathyroidism (sHPTH) fails, total parathyroidectomy with autotransplantation of parathyroid tissue into the forearm (PTX-AT) is the most widely used procedure, but high recurrence rates are reported.

Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study

Recurrent glioblastoma (GBM) is a disease with poor prognosis for which there is no established standard therapy. A recent survey among Swiss neuro-oncology centres has shown considerable differences in treatment recommendations.

Supplementum 242: Abstracts of the 51st Annual meeting of the Swiss Society of Nephrology